AAPGV - Ascentage Debt to Book Capitalization Ratio

Brandmark of Ascentage Pharma Group International (AAPGV)

Ascentage Pharma Group (AAPGV) is maneuvering between US and PRC regulators to protect its research. The ratio of total liabilities to book capitalization illustrates the financial leverage dynamics, where the 3.46 metric determines this level. Balance sheet stability is supported by grants from global partners, while the competitive advantage is based on a unique inhibitor platform that blocks tumor cell survival at the molecular level.

AAPGV (Ascentage) Debt to Book Value history from 01/25/2025 to 10/28/2026
Core merchandise of Ascentage

For Ascentage Pharma Group (AAPGV), this indicator determines the stability of financial leverage amid the development of costly drugs. The metric compares total liabilities to the book value of equity, measuring the business's degree of dependence on external financing. By analyzing the capital structure trend—debt to book capitalization—an investor can observe solvency dynamics prior to the release of financial reports. Amid geopolitical tensions between the US and China, low leverage minimizes bankruptcy risks should global drug registration slow down. An optimal debt balance here ensures the company's survival in an environment of limited access to international capital.

Competitors of Ascentage Pharma Group (AAPGV)

Debts to Book Capitalization ONC (BeiGene Ltd)|halozyme.com - Debts to Book Capitalization|Revolution Medicines, Inc. (RVMD) - Debt to Book Capitalization Ratio|AAPG - Debt to Book Value Ratio|CGON (CG Oncology Corp) - Debts to Book Capitalization|UroGen Pharma Corp (URGN) - Debt to Book Value|Debts to Book Capitalization BCAX (Bicara Therapeutics Inc.)|Debts to Book Value PSNL|Erasca (ERAS) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Delcath Systems Inc DCTH|Debt to Book Value YmAbs|Debt to Net Assets Ratio Aura Corp AURA|CADL: Debts to Book Capitalization|accuray.com (ARAY) - Debt to Book Value|SLS: Debt to Book Value|ACTU (Actuate Therapeutics Inc.) - Debts to Book Capitalization|CTOR - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio TuHURA|Protara Therapeutics - Debts to Book Capitalization|Debts to Book Value fatetherapeutics.com (FATE)|Debts to Book Capitalization WHWK (Aadi Bioscience)|TScan Therapeutics Inc - Debts to Book Capitalization|Debt to Book Capitalization Ratio CSBR (Champions Oncology Corp)|XBIT - Debts to Net Assets|CVM (cel-sci.com) - Debts to Book Capitalization|ostherapies.com (OSTX) - Debt to Book Value|Debts to Book Capitalization RADX (Radiopharm Theranostics Limited)|Debts to Book Value ARTV|Debt to Book Capitalization Ratio Adlai Nortye Ltd. ANL|Debt to Book Value Ratio Veru Corporation VERU|Debt to Book Value Tempest Therapeutics (TPST)|Debt to Book Capital Xilio Therapeutics Inc XLO|Enochian BioSciences - Debts to Book Capitalization|MURA - Debts to Book Capitalization|Debts to Book Capitalization KAPA (kairospharma.com)|OnKure Therapeutics (OKUR) - Debt to Net Assets|Debts to Book Capitalization GDTC (CytoMed Therapeutics Ltd)|Debts to Book Value Curis Corp (CRIS)|Apollomics, Inc. (APLM) - Debt to Book Value|Debt to Net Assets Ratio THAR (Tharimmune Inc)|Advanced Biomed (ADVB) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Genprex Inc GNPX|Debts to Book Capitalization Calidi Bio (CLDI)|SBFM - Debt to Net Assets Ratio|XBIO: Debts to Book Capitalization|SLRX (Salarius Pharmaceuticals Inc) - Debts to Book Capitalization|PPBT - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio AONC|Debt to Book Capitalization Ratio BGNE (BeiGene, Ltd.)|Debt to Book Value checkpointtx.com (CKPT)|Debts to Book Capitalization ELEV (Elevation Oncology, Inc.)|ICAD - Debts to Book Capitalization|Debt to Book Value Ikena (IKNA)|NTBL - Debt to Net Assets Ratio|Debts to Book Capitalization VIRX (viracta.com)|MOR (morphosys.com) - Debt to Net Assets|NAYA - Debt to Book Capitalization Ratio